Asston Pharmaceuticals Ltd

ASSTON PHARMACEUTICALS LIMITED

Asston Pharmaceuticals has informed BSE about the appointment of a new statutory auditor.

ASSTON PHARMACEUTICALS LIMITED

Asston Pharmaceuticals has informed BSE about the appointment of a new statutory auditor.

ASSTON PHARMACEUTICALS LIMITED

Asston Pharmaceuticals has informed BSE about the appointment of a new statutory auditor.

ASSTON PHARMACEUTICALS LIMITED

Asston Pharmaceuticals has informed BSE about the appointment of a new statutory auditor.

ASSTON PHARMACEUTICALS LIMITED

Aston Pharmaceuticals has informed BSE about the appointment of a new statutory auditor.

ASSTON PHARMACEUTICALS LIMITED

Asston Pharmaceuticals has informed BSE about the appointment of a new statutory auditor.

ASSTON PHARMACEUTICALS LIMITED

Asston Pharmaceuticals has informed BSE about the appointment of a new statutory auditor.

ASSTON PHARMACEUTICALS LIMITED

Asston Pharmaceuticals has informed BSE about the appointment of a new statutory auditor.

ASSTON PHARMACEUTICALS LIMITED

Asston Pharmaceuticals has informed BSE about the appointment of a new statutory auditor.

Asston Pharmaceuticals Ltd

Asston Pharmaceuticals Ltd has announced a change in management, with the appointment of Mr. Ashish Narayan Sakalkar as Managing Director and the re-appointment of Mr. Sakalkar as Director retiring by rotation. The company has also approved the appointment of M/s Panchal S K & Associates as Statutory Auditors and increased the remuneration of Mr. Sakalkar, Mrs. Saili Jayaram More, and Mr. Sachin Chandrakant Badakh.

Asston Pharmaceuticals Ltd

Asston Pharmaceuticals Ltd has announced the appointment of Mr. Ashish Narayan Sakalkar as Director retiring by rotation and re-appointment, and M/s Panchal S K & Associates as Statutory Auditors of the Company.

Asston Pharmaceuticals Ltd

Asston Pharmaceuticals Ltd has submitted the Scrutinizer's Report along with the voting results of the 7th Annual General Meeting held on 29th September, 2026. The meeting was conducted through video conferencing, and the resolutions passed include the adoption of audited financial statements, appointment of a managing director, and appointment of statutory auditors.

Asston Pharmaceuticals Ltd

Asston Pharmaceuticals Ltd held its 7th Annual General Meeting on 29.09.2026 via Video Conferencing facility. The meeting was attended by the Managing Director, Whole Time Director and CEO, Independent Directors, Non-Executive Directors, Company Secretary, Chief Financial Officer, Statutory Auditor, and Scrutinizer. The resolutions proposed to be passed at this AGM were explained to the shareholders, and the window for electronic voting remained open till 15 minutes post the conclusion of the AGM.

Asston Pharmaceuticals Ltd

Asston Pharmaceuticals Ltd has announced the closure of its trading window for all designated persons from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the half year ended September 30, 2026.

Asston Pharmaceuticals Ltd

Asston Pharmaceuticals Ltd received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Prakruti R Pali, indicating a change in promoter holding from 7.26% to 9.03% through open market purchases.

Asston Pharmaceuticals Ltd

Asston Pharmaceuticals Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Prakruti R Pali, indicating a significant acquisition of shares in the company.

Asston Pharmaceuticals Ltd

Asston Pharmaceuticals Ltd has received a disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Prakruti R Pali, which will be submitted to the BSE.

Asston Pharmaceuticals Ltd

Asston Pharmaceuticals Ltd has received a disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Prakruti R Pali.

Asston Pharmaceuticals Ltd

Asston Pharmaceuticals Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 04/09/2026 to consider and approve various matters, including the appointment of a new statutory auditor, increase in remuneration of directors, and the date and draft notice of the 7th Annual General Meeting.

Asston Pharmaceuticals Ltd

Asston Pharmaceuticals Ltd has announced the voting results and scrutinizer's report for its Extraordinary General Meeting (EGM) held on July 31, 2026, through video conferencing. The meeting was attended by 3 promoters and 0 public shareholders, and 1 resolution was passed, which was to issue equity shares on a preferential basis.